January 2024 in “International Journal of Advanced Computer Science and Applications” Deep learning and explainable AI are improving scalp disorder diagnosis, but challenges in transparency and data quality remain.
Isotretinoin may cause temporary, reversible facial hair growth in some women.
The model accurately predicts hair loss severity in alopecia areata.
25 citations
,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
22 citations
,
January 2015 in “Dermatology Research and Practice” An extra-strength marine protein supplement helped increase hair growth and decrease hair shedding in women with thinning hair.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
1 citations
,
April 2023 in “Archives of Dermatological Research” Skin emergency severity rises with other health issues and affects multiple organs; a new grading system can improve patient care.
May 2026 in “International Journal of Homoeopathic Sciences” Individualized Homeopathic Medicine shows promise for treating alopecia with lasting hair regrowth.
April 2025 in “International Journal of Homoeopathic Sciences” Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
Men with male pattern baldness may have a higher risk of heart problems.
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
May 2021 in “Indian journal of forensic medicine and toxicology” Females with androgenic alopecia have significantly lower vitamin D3 and ferritin levels.
2 citations
,
November 2015 in “Journal of Investigative Dermatology Symposium Proceedings” A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
15 citations
,
September 2018 in “Dermatologic therapy” Both emollients effectively reduced itching and improved skin moisture in xerotic eczema.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
1 citations
,
February 2022 in “Lasers in Medical Science” Low-level laser therapy is about 80% effective in treating hair loss, with best results in males, those who use it for over a year, and those with scalp conditions like dandruff and rash.
STS01 1% effectively promotes hair regrowth with minimal side effects.
March 2026 in “Cosmoderma” Venusia CeraPlus cream and lotion effectively reduce eczema severity and improve skin moisture.
January 2026 in “Dermatology and Therapy” Poor sleep may lead to hair loss, and hair loss may affect sleep.
November 2025 in “International Journal of Pharmaceutical Sciences and Drug Research” Thyroid disorders significantly affect the well-being of married, urban, non-working individuals in South India.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.